This page provides investment landscape analysis for oxidative stress-targeted therapeutics in neurodegenerative diseases, tracking companies, investors, therapeutic approaches, and pipeline metrics. Data is derived from ClinicalTrials.gov and industry sources as of March 2026.
Oxidative stress is a hallmark of neurodegenerative diseases, driven by accumulated reactive oxygen species (ROS) that damage proteins, lipids, and DNA in neurons. The brain's high metabolic demand and limited antioxidant capacity make it particularly vulnerable to oxidative damage. This investment landscape examines the current therapeutic pipeline targeting oxidative stress mechanisms across Alzheimer's disease, Parkinson's disease, ALS, and other neurodegenerative conditions. [1]
Oxidative stress-targeted therapies represent a significant opportunity in neurodegeneration drug development, with approximately 85-95 active trials across the field. The majority of approaches focus on mitochondrial antioxidants, Nrf2 pathway activation, and glutathione enhancement. Despite strong biological rationale, translation to effective therapeutics has been challenging, with only a few agents achieving regulatory approval for specific indications. [2]
Key investment themes include:
Based on ClinicalTrials.gov data and industry pipeline tracking, the oxidative stress therapeutic pipeline includes:
| Phase | Number of Trials | Percentage |
|---|---|---|
| Pre-clinical | ~60+ | — |
| Phase 1 | 8 | 22% |
| Phase 2 | 18 | 49% |
| Phase 3 | 7 | 19% |
| Approved (ND-specific) | 2 | 5% |
| Approved (off-label/repurposed) | 3 | 8% |
| Drug | Company | Mechanism | Approval Year | Indication |
|---|---|---|---|---|
| Edaravone | Mitsubishi Tanabe/Medical Use | Free radical scavenger | 2017/2015 | ALS (Japan/US) |
| Coenzyme Q10 | Various | Mitochondrial electron transport | Off-label | Parkinson's, CoQ10 deficiency |
| Vitamin E | Various | Lipid-soluble antioxidant | Off-label | AD, MCI |
Note: Most approved uses are off-label or in specific geographic regions.
Targeting mitochondrial ROS production and enhancing electron transport chain function:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| MitoQ | Small molecule | MitoQ Limited | Phase 2 | Mitochondrial CoQ |
| Ubiquinol-10 | Small molecule | Kaneka | Phase 3 | Mitochondrial CoQ |
| EPI-743 | Small molecule | Refoxy Pharmaceuticals | Phase 2/3 | Mitochondrial function |
| AAV-MCK-NQO1 | Gene therapy | Various | Pre-clinical | NQO1 overexpression |
Key Targets: Complex I/III ROS, CoQ10 deficiency, mitochondrial membrane potential
Activating the master regulatory pathway for antioxidant response:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| Sulforaphane | Small molecule | Evgen Pharma/Cambridge | Phase 2 | Nrf2 activation |
| Bardoxolone methyl | Small molecule | Kyowa Hakko Kirin | Phase 2 | Nrf2 activator |
| Dimethyl fumarate | Small molecule | Biogen | Approved | Nrf2 activator (MS) |
| DH404 | Small molecule | Reata Pharmaceuticals | Pre-clinical | Nrf2 activator |
Key Targets: NRF2-KEAP1 pathway, ARE-driven antioxidant genes [3]
Boosting cellular glutathione levels to counter ROS:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| NACET | Small molecule | Evidentia | Phase 3 | GSH precursor |
| GSH (IV) | Small molecule | Multiple | Phase 2 | Glutathione replacement |
| BSO inhibitor | Small molecule | Various | Pre-clinical | GSH synthesis inhibition |
| NAC | Small molecule | Multiple | Off-label | GSH precursor |
Key Targets: GSH depletion, GCLM, GCLC [4]
Synthetic superoxide dismutase catalysts:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| GC4419 | Small molecule | Galera Therapeutics | Phase 2 | SOD mimetic |
| AEOL-10150 | Small molecule | Aeolus Pharmaceuticals | Pre-clinical | SOD mimetic |
| EPI-743 | Small molecule | Refoxy | Phase 2/3 | Redox regulator |
Emerging approaches targeting peroxiredoxin system:
| Therapy | Type | Company | Phase | Target |
|---|---|---|---|---|
| Prdx6 activators | Small molecule | Various | Pre-clinical | Prdx6 |
| Indication | Active Trials | Key Mechanisms |
|---|---|---|
| Alzheimer's Disease | ~25 | MitoQ, Nrf2 activators, GSH enhancers |
| Parkinson's Disease | ~30 | CoQ10, mitochondrial targets, Nrf2 |
| ALS | ~15 | Edaravone, EPI-743, mitochondrial |
| Huntington's Disease | ~8 | MitoQ, Nrf2, GSH |
| Multiple Sclerosis | ~12 | Dimethyl fumarate (approved) |
Oxidative stress in neurodegenerative diseases: A2. Molecular Neurobiology. 2023. ↩︎
ClinicalTrials.gov Oxidative Stress Filter. https://clinicaltrials.gov. ↩︎
Nrf2-KEAP1 pathway in neurodegeneration. Nature Reviews Neuroscience. 2024. ↩︎
Glutathione in neurodegenerative disease. Free Radical Biology and Medicine. 2023. ↩︎